Heartflow sues AI rival Cleerly | Another win for opportunistic screening | Predicting TAVR outcomes | Key approvals for Abbott

According to Heartflow, Cleerly's actions represent “one of the most egregious examples of piracy in the medical technology industry.” Cleerly commented on the lawsuit, defending the value and integrity of its products. 

AI can help care teams get additional value out of routine head CT images.

As TAVR continues to gain popularity, researchers remain focused on discovering new ways to predict short- and long-term outcomes. One recent study, for example, explored the potential of AI-enabled imaging assessments. Another analysis focused on the CALLY index.

Ultreon 3.0 was built to capture and evaluate OCT images, providing real-time guidance during complex PCI procedures.

An advanced algorithm that looks for signs of heart failure in five-second voice recordings has received the FDA's breakthrough device designation.

This is the second FDA clearance in two weeks for Massachusetts-based Anumana. The company's AI models are built to evaluate ECG results for signs of various cardiovascular conditions.

Afnan Tariq, MD, discusses early data on a passive, device-agnostic AI platform for heart failure monitoring. “When clinicians are empowered with insights and able to act earlier, you're able to have a durable impact," he said.